Europe Fights To Regenerate Its Abandoned Pharma R&D Sites
Last month's announcement that Pfizer Inc. plans to close its flagship U.K. R&D operations in Sandwich, Kent, is but the latest example of how major shifts in Big Pharma's business and research strategies are exacting a heavy toll on long-established facilities.
You may also be interested in...
British life sciences minister George Freeman has launched ambitious plans to speed access to drugs by cutting drug development times by a third – but his plans face many hurdles.
The third biotech company to be spun out of GlaxoSmithKline’s unwanted neurosciences R&D is NeRRe Therapeutics, which has a neurokinin antagonist ready for Phase II clinical studies in an undisclosed indication.
Merck KGaA is in learning mode as it calls for early retirements and voluntary redundancies in Germany, instead of more abrupt action. Around 10% of jobs at Merck KGaA in Germany are at risk, but the company will refrain from forced job losses until the end of 2017.